Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'
Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'
On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company's TEAD1- selective Hippo pathway inhibitor, and continued clinical development of IK-595, a novel MEK-RAF molecular glue.
周二，Ikena Oncology Inc（纳斯达克股票代码：IKNA）停止了临床 IK-930 计划、该公司的 TEAD1 选择性Hippo途径抑制剂，并继续对新型MEK-RAF分子胶水 IK-595 进行临床开发。
Concurrently, Ikena is evaluating strategic options for the company and its development pipeline.
同时，Ikena正在评估公司的战略选择及其开发渠道。
The company said that based on a review of clinical data to date, available resources, and strategic priorities, the company decided to discontinue the development of IK-930.
该公司表示，根据对迄今为止的临床数据、可用资源和战略优先事项的审查，该公司决定停止开发 IK-930。
The IK-930 Phase 1 program will begin winding down activities; treatment will continue for enrolled patients who have derived benefits.
IK-930 第一阶段计划将开始结束活动；将继续对获得收益的入组患者进行治疗。
The company will seek strategic options for the program, including potential partners for developing IK-930 in combination with other targeted agents.
该公司将为该计划寻求战略选择，包括与其他目标药物联合开发 IK-930 的潜在合作伙伴。
In November 2023, Ikena shared initial data from twenty-six patients treated in the ongoing dose escalation portion of the Phase 1 trial of IK-930.
2023 年 11 月，Ikena 分享了在 IK-930 一期试验正在进行的剂量递增部分接受治疗的 26 名患者的初步数据。
In connection with the discontinuation of IK-930 development, the company is executing a workforce reduction of approximately 53%
由于停止开发 IK-930，该公司正在裁员约53％
Ikena reported $157 million in cash, cash equivalents, and marketable securities as of March 31, 2024.
截至2024年3月31日，Ikena报告了1.57亿美元的现金、现金等价物和有价证券。
William Blair writes, "The discontinuation of IK-930 is clearly a disappointment, as it removes the potential for a meaningful clinical catalyst later this year with the updated formulation following a disappointing initial clinical readout in the fall of 2023."
威廉·布莱尔写道：“IK-930 的停产显然令人失望，因为在 2023 年秋季的初步临床数据令人失望之后，更新后的配方消除了在今年晚些时候开发有意义的临床催化剂的可能性。”
The analyst adds, "We believe clear single-agent activity with IK-595 will be needed to generate significant interest and share appreciation beyond the cash balance." William Blair maintains an Outperform rating.
该分析师补充说：“我们认为，除了现金余额外，还需要进行明确的单一代理人活动，才能产生可观的利息和股票增值。” IK-595威廉·布莱尔维持跑赢大盘的评级。
Management expressed enthusiasm about IK-595's profile and its potential for a simpler development path in significantly larger market opportunities.
管理层对 IK-595 的概况及其在更大的市场机会中更简单的发展道路的潜力表示了热情。
Wedbush writes, "While IK-595 showed encouraging preclinical activity against multiple xenograft models of cancers with different RAS/MAPK alterations, we are moving to the sidelines regarding shares until management discloses more data and development plans for the asset, given the competition in the space."
韦德布什写道：“尽管 IK-595 针对具有不同 RAS/MAPK 变化的多种癌症异种移植模型的临床前活动令人鼓舞，但鉴于该领域的竞争，在管理层披露更多资产数据和开发计划之前，我们在股票问题上处于观望状态。”
Wedbush has downgraded the stock to Neutral from Outperform, cutting the price target to $2 from $8.
Wedbush已将该股的评级从跑赢大盘下调至中性，将目标股价从8美元下调至2美元。
Price Action: IKNA shares are up 23.30% at $1.64 at the last check on Wednesday.
价格走势：在周三的最后一次支票中，IKNA股价上涨23.30％，至1.64美元。